中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

丙型肝炎病毒感染与治疗药物

戚中田

戚中田. 丙型肝炎病毒感染与治疗药物[J]. 临床肝胆病杂志, 2011, 27(1): 15-18+27.
引用本文: 戚中田. 丙型肝炎病毒感染与治疗药物[J]. 临床肝胆病杂志, 2011, 27(1): 15-18+27.
Qi ZhongTian. Hepatitis C virus infection and its therapeutic drugs[J]. J Clin Hepatol, 2011, 27(1): 15-18+27.
Citation: Qi ZhongTian. Hepatitis C virus infection and its therapeutic drugs[J]. J Clin Hepatol, 2011, 27(1): 15-18+27.

丙型肝炎病毒感染与治疗药物

详细信息
  • 中图分类号: R512.63

Hepatitis C virus infection and its therapeutic drugs

  • 摘要:

    丙型肝炎病毒(HCV)通过在宿主细胞内持续复制,导致慢性感染。目前用于治疗慢性丙型肝炎(CHC)的药物主要是聚乙二醇干扰素(PEG-IFN)和利巴韦林的联合用药。本文将就HCV的细胞入侵、复制、逃避宿主的固有和获得性免疫,以及抗HCV临床试验药物的最新进展做一综述。

     

  • [1]Nakano T, Lu L, He Y, et al.Population genetic history of hepatitis C virus 1b infection in China[J].J Gen Virol, 2006, 87 (Pt 1) :73-82.
    [2]Kemmer N, Neff GW.Managing chronic hepatitis C in the difficult-to-treat patient[J].Liver Int, 2007, 27 (10) :1297-1310.
    [3]Hughes CA, Shafran SD.Chronic hepatitis C virus management:2000-2005 update[J].Ann Pharmacother, 2006, 40 (1) :74-82.
    [4]Bartosch B, Dubuisson J, Cosset FL.Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes[J].J Exp Med, 2003, 197 (5) :633-642.
    [5]Lindenbach BD, Evans MJ, Syder AJ, et al.Complete replication of hepatitis C virus in cell culture[J].Science, 2005, 309 (5734) :623-626.
    [6]Wakita T, Pietschmann T, Kato T, et al.Production of infectious hepatitis C virus in tissue culture from a cloned viral genome[J].Nat Med, 2005, 11 (7) :791-796.
    [7]Pileri P, Uematsu Y, Campagnoli S, et al.Binding of hepatitis C virus to CD81[J].Science, 1998, 282 (5390) :938-941.
    [8]Grove J, Huby T, Stamataki Z, et al.Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity[J].J Virol, 2007, 81 (7) :3162-3169.
    [9]Kapadia SB, Barth H, Baumert T, et al.Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I[J].J Virol, 2007, 81 (1) :374-383.
    [10]Evans MJ, von HT, Tscherne DM, et al.Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry[J].Nature, 2007, 446 (7137) :801-805.
    [11]Liu S, Yang W, Shen L, et al.Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection[J].J Virol, 2009, 83 (4) :2011-2014.
    [12]Timpe JM, Stamataki Z, Jennings A, et al.Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies[J].Hepatology, 2008, 47 (1) :17-24.
    [13]Pietschmann T.Virology:Final entry key for hepatitis C[J].Nature, 2009, 457 (7231) :797-798.
    [14]Griffin SD, Beales LP, Clarke DS, et al.The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine[J].FEBS Lett, 2003, 535 (1-3) :34-38.
    [15]Pietschmann T, Kaul A, Koutsoudakis G, et al.Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras[J].Proc Natl Acad Sci U S A, 2006, 103 (19) :7408-7413.
    [16]Noppornpanth S, Lien TX, Poovorawan Y, et al.Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus[J].J Virol, 2006, 80 (15) :7569-7577.
    [17]Gosert R, Egger D, Lohmann V, et al.Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons[J].J Virol, 2003, 77 (9) :5487-5492.
    [18]Watashi K, Ishii N, Hijikata M, et al.Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase[J].Mol Cell, 2005, 19 (1) :111-122.
    [19]Li K, Foy E, Ferreon JC, et al.Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF[J].Proc Natl Acad Sci U S A, 2005, 102 (8) :2992-2997.
    [20]Meylan E, Curran J, Hofmann K, et al.Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus[J].Nature, 2005, 437 (7062) :1167-1172.
    [21]Sarrazin C, Rouzier R, Wagner F, et al.SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders[J].Gastroenterology, 2007, 132 (4) :1270-1278.
    [22]Inchauspe G, Feinstone S.Development of a hepatitis C virus vaccine[J].Clin Liver Dis, 2003, 7 (1) :243-259.
    [23]Chapel C, Garcia C, Roingeard P, et al.Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles[J].J Gen Virol, 2006, 87 (Pt 4) :861-871.
    [24]Inoue K, Umehara T, Ruegg UT, et al.Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo[J].Hepatology, 2007, 45 (4) :921-928.
    [25]Whitby K, Taylor D, Patel D, et al.Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV:implications for the treatment of hepatitis C[J].Antivir Chem Chemother, 2004, 15 (3) :141-151.
  • 加载中
计量
  • 文章访问数:  4274
  • HTML全文浏览量:  4
  • PDF下载量:  1578
  • 被引次数: 0
出版历程
  • 出版日期:  2011-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回